Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.

Authors:
Putman MS; Norris AW; Hull RL; Rickels MR; Sussel L and 15 more

Journal:
Diabetes

Publication Year: 2023

DOI:
10.2337/db22-0949

PMCID:
PMC10202770

PMID:
37125945

Journal Information

Full Title: Diabetes

Abbreviation: Diabetes

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Duality of Interest. M.S.P. reports research grants from Dexcom, Inc., and Vertex Pharmaceuticals and speaking fees from Vertex Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported."

Evidence found in paper:

"Funding. M.R.R. and A.K. are supported in part by Public Health Service Research Grant R01 DK97830. A.K. is supported by grants from the Cystic Fibrosis Foundation. A.W.N. and J.F.E. are supported in part by grants R01 DK115791, RC2 DK124207, and P30 DK054759. T.D., A.A.S., and J.A.A. are supported in part by National Institutes of Health (NIH) grant P30 DK125013. M.S.P. is supported by R01 DK119699 and grants from the Cystic Fibrosis Foundation. A.M. is supported by NIH grant R01 DK101402. J.A.A. is supported by NIH grant R01 DK133523, Cystic Fibrosis Foundation grant ALVARE19A0, and Cystic Fibrosis Foundation grant ALVARE22A0. K.L.O. is supported in part by P30 DK054759 and grants from the Cystic Fibrosis Foundation."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025